A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Conditions

• Obesity
• Overweight

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Tirzepatide — DRUG
  Administered SC
• Placebo — DRUG
  Administered SC

Study Details

The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.

Key Dates

Start date

Sep 20, 2023

Status verified

Mar 2026

Primary completion

Jan 20, 2026

Completion

Jan 20, 2026

Study Design

Enrollment

441 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Tirzepatide 5 milligram (mg)
  Participants will receive tirzepatide subcutaneously (SC).
• Experimental: Tirzepatide Maximum Tolerated Dose
  Participants will receive tirzepatide SC.
• Placebo Comparator: Placebo
  Participants will receive placebo.

Primary Outcome Measure

Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period [ Time Frame: Week 112 ]

Locations (20)

Related coverage on Hipa.ai

• Tirzepatide Phase 3 Study for Weight Reduction Maintenance Completes Primary
  Tirzepatide · Jan 20, 2026 · ClinicalTrials.gov

Find similar trials in Pelham, AL

Related Studies

• Metabolic Effects of Angiotensin-(1-7)
  PHASE1 · Recruiting · Vanderbilt University · Nashville, Tennessee
• Inflammation, Diabetes, Ethnicity and Obesity Cohort
  Recruiting · University of California, San Francisco · San Francisco, California
• Physiologic and Functional Adaptations of Insulin Sensitive Tissues
  Enrolling By Invitation · Vanderbilt University Medical Center · Nashville, Tennessee
• Modifying Diet to Improve Gut Microbiome
  Not Yet Recruiting · H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida